Intravenous and Subcutaneous Immunoglobulin Replacement: A Two-Way Road. Optimizing Healthcare Quality in Patients with Primary Immunodeficiencies

Journal of Clinical Immunology

Volumn 34, Issue 8, 2014, Pages 1015-1017

  Soler Palacín, Pere ^a   Gasó Gago, Ingrid ^b   Fernández Polo, Aurora ^b   Martín Nalda, Andrea ^a   Oliveras, María ^b   Martinez Cutillas, Julio ^b   Figueras, Concepció ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Intravenous immunoglobulins; primary immunodeficiency; quality of life; subcutaneous immunoglobulins

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADOLESCENT; AGAMMAGLOBULINEMIA; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD CLOTTING DISORDER; CHILDHOOD DISEASE; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE QUALITY; HOSPITAL ADMISSION; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION; LEISURE; MALE; OBSERVATIONAL STUDY; QUALITY OF LIFE; RETROSPECTIVE STUDY; SYSTEMIC DISEASE; TREATMENT DURATION; TREMOR; UNIVERSITY HOSPITAL; ADULT; CHILD; HEALTH CARE DELIVERY; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; PRESCHOOL CHILD; STANDARDS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DELIVERY OF HEALTH CARE; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INFUSIONS, SUBCUTANEOUS; MALE; RETROSPECTIVE STUDIES;

EID: 84911979412     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-014-0096-2     Document Type: Article

References (27)

1. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105–16.
2. Gardulf A, Hammarström L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.
3. Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol. 2002;104:237–41.
4. Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, et al. Immunodeficiencies. Clin Exp Immunol. 2009;158 Suppl 1:14.
5. European Society for Immunodeficiencies. PID Care in Development. [Consultado el 8 de Abril de 2014]. Available in http://dev.esid.org/pid-care-pid-care-in-development-wp-news-at-esid-fall-2012-472-0
6. European Society for Immunodeficiencies. Additional Statistics. [Consultado el 30 de noviembre de 2013]. Available in http://esid.org/Working-Parties/Registry/ESID-Database-Statistics
7. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.
8. Chouksey A, Duff K, Wasserbauer N, Berger M. Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin Immunol. 2005;1(3):120–30.
9. Melamed I, McDonald A, Neff A, Beck A. An analysis of safety and tolerability data on 10 %, 16 %, and 20 % formulations of subcutaneous immunoglobulin (IGSC). J Allergy Clin Immunol. 2011;127:AB16.
10. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101:114–21.
11. Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J. 1997;16:696–707.
12. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133–41.
13. Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013;73(12):1307–19.
14. Shapiro RS. Why I, use subcutaneous immunoglobulin (SCIG). J Clin Immunol. 2013;33 Suppl 2:S95–8.
15. Torgerson TR. Overview of routes of IgG administration. J Clin Immunol. 2013;33 Suppl 2:S87–9.
16. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32(6):1153–64.
17. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32(6):1180–92.
18. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IG self-infusions at home. J Allergy Clin Immunol. 2004;114:936–42.
19. Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856–63.
20. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65–72.
21. Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28:370–8.
22. Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15:238–45.
23. Torgerson T, Bonagura V, Shapiro R. Clinical ambiguities—ongoing questions. J Clin Immunol. 2013;33 Suppl 2:S99–103.
24. Torgerson T. Comparing routes of IgG administration for primary immunodeficiency disorders. Clin Immunol. 2013;33 Suppl 2:S85–6.
25. Maroto Hernando M, Soler-Palacín P, Martin-Nalda N, Oliveras Arenas M, Español Boren T, Figueras NC. Subcutaneous gammaglobulin in common variable immunodeficiency: first experience in Spain. An Pediatr. 2009;70:111–9.
26. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48–51.
27. Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10 % caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518–26.